资料显示，中国核工业建设股份有限公司位于上海市青浦区蟠龙路500号中核科创园，成立日期2010年 12月21日，上市日期2016年6月6日，公司主营业务涉及军工工程、核电工程和工业与民用工程建设。主 营业务收入构成为：工业与民用工程56.81%，核电工程33.20%，其他9.99%。 中国核建所属申万行业为：建筑装饰-基础建设-基建市政工程。所属概念板块包括：融资融券、央企改 革、一带一路、中字头、中特估等。 截至9月30日，中国核建股东户数9.10万，较上期增加0.69%；人均流通股33130股，较上期减少0.69%。 2025年1月-9月，中国核建实现营业收入739.38亿元，同比减少6.32%；归母净利润11.06亿元，同比减少 23.96%。 分红方面，中国核建A股上市后累计派现17.87亿元。近三年，累计派现8.14亿元。 资金流向方面，主力资金净流出1132.90万元，特大单买入108.24万元，占比0.93%，卖出293.51万元， 占比2.52%；大单买入1606.09万元，占比13.81%，卖出2553.73万元，占比21.95%。 中国核建今年以来股价涨27.91%，近5个交易日跌5.77 ...

Group 1 - EVE Energy signed a procurement framework agreement with its affiliate, Smoore International, for continuous procurement of battery cells starting from January 1, 2026 [1] - Zhaoyi Information plans to issue H-shares and list on the Hong Kong Stock Exchange [1] - Fuke Environmental announced a change in its stock abbreviation to "Fuke Technology" effective November 26 [1] Group 2 - Dajia Weikang's shareholder and director terminated a share reduction plan ahead of schedule, having reduced 1% of total shares [2] - Aohong Electronics received approval from the China Securities Regulatory Commission for the issuance of convertible bonds [2] - Yingfeng Environment's controlling shareholder plans to issue exchangeable bonds not exceeding 1 billion yuan [2] Group 3 - Longshen Rongfa's subsidiary obtained a renewed drug production license covering various pharmaceutical products [4] - Xinhua News' subsidiary invested 15 million yuan in a fund with a total commitment of 221 million yuan [5] - Guang'an Aizhong appointed two new deputy general managers [6] Group 4 - Fosun Pharma's subsidiary's drug for gastric cancer treatment was included in the breakthrough therapy program by the National Medical Products Administration [7] - Nanjiao Foods reported a significant decline in October net profit due to rising raw material costs [8] - Nanfeng Co. won two nuclear power project bids totaling 928.7 million yuan [10] Group 5 - Puluo Pharmaceutical received a drug registration certificate for its Cefdinir capsules [11] - Liming Co.'s subsidiary received environmental approval for a new pesticide raw material project [12] - Longhua New Materials' expansion project for polyether polyols has commenced trial production [13] Group 6 - Pumen Technology's products received IVDR CE certification from TÜV Rheinland [15] - China Chemical reported new contracts worth 312.67 billion yuan from January to October [18] - China Nuclear Construction achieved new contracts totaling 123.84 billion yuan as of October [19] Group 7 - Changshu Bank's executives plan to purchase at least 550,000 shares of the bank [20] - Shandong Steel's subsidiary is applying for bankruptcy liquidation to focus on core business [21] - Huakang Clean is expected to win a bid for a purification system project worth 176 million yuan [23] Group 8 - Huawu Co. plans to internally transfer subsidiary equity [24] - Tianen Kang's subsidiary received clinical trial acceptance for a new drug [26] - Tianyi Medical's subsidiary obtained a medical device registration certificate for a blood dialysis product [27] Group 9 - Xuelang Environment is facing a pre-restructuring application from creditors [27] - Chitianhua's subsidiary resumed production after passing safety inspections [28] - Huaping Co.'s director plans to reduce 0.03% of company shares [30] Group 10 - Xizhuang Co. plans to establish a wholly-owned subsidiary in Singapore [31] - Ruisheng Intelligent's subsidiary won a 60.23 million yuan ICT project bid [32] - Junyi Digital plans to invest 120 million yuan in Guanghong Precision [33] Group 11 - Fuguang Co.'s controlling shareholder plans to increase holdings between 80 million to 150 million yuan [34] - Ganyue Express reported a 13.68% increase in logistics revenue in October [39] - Jiangsu Sop terminated its 2025 private placement plan [41] Group 12 - Langke Intelligent's shareholders plan to reduce a total of 1.68% of company shares [42] - Yuantong Express reported an 8.97% increase in express product revenue in October [45] - Jinbei Automotive plans to invest 158 million yuan to acquire 52% of Zhongtuo Technology [46]

11月20日，宏润建设盘中下跌2.08%，截至10:58，报9.43元/股，成交7804.78万元，换手率0.73%，总市 值116.67亿元。 宏润建设所属申万行业为：建筑装饰-基础建设-基建市政工程。所属概念板块包括：盾构机、机器人概 念、长三角一体化、工业4.0、铁路基建等。 截至9月30日，宏润建设股东户数3.52万，较上期增加2.55%；人均流通股31972股，较上期减少2.48%。 2025年1月-9月，宏润建设实现营业收入42.62亿元，同比减少0.47%；归母净利润2.44亿元，同比减少 2.41%。 分红方面，宏润建设A股上市后累计派现12.93亿元。近三年，累计派现3.42亿元。 资金流向方面，主力资金净流出679.04万元，特大单买入145.60万元，占比1.87%，卖出317.78万元，占 比4.07%；大单买入1758.64万元，占比22.53%，卖出2265.50万元，占比29.03%。 宏润建设今年以来股价涨88.19%，近5个交易日跌7.37%，近20日跌16.25%，近60日涨29.36%。 今年以来宏润建设已经3次登上龙虎榜，最近一次登上龙虎榜为11月3日，当日龙虎榜净买入 ...

中国核建今年以来股价涨32.16%，近5个交易日跌10.53%，近20日跌4.83%，近60日涨27.40%。 11月20日，中国核建盘中下跌2.07%，截至10:28，报11.81元/股，成交2.62亿元，换手率0.73%，总市值 355.93亿元。 今年以来中国核建已经4次登上龙虎榜，最近一次登上龙虎榜为10月31日，当日龙虎榜净买入-5.21亿 元；买入总计1.99亿元 ，占总成交额比5.95%；卖出总计7.20亿元 ，占总成交额比21.53%。 资料显示，中国核工业建设股份有限公司位于上海市青浦区蟠龙路500号中核科创园，成立日期2010年 12月21日，上市日期2016年6月6日，公司主营业务涉及军工工程、核电工程和工业与民用工程建设。主 营业务收入构成为：工业与民用工程56.81%，核电工程33.20%，其他9.99%。 资金流向方面，主力资金净流出1982.05万元，特大单买入1458.63万元，占比5.56%，卖出2084.64万 元，占比7.95%；大单买入4616.50万元，占比17.61%，卖出5972.54万元，占比22.78%。 机构持仓方面，截止2025年9月30日，中国核建十大流 ...

Group 1 - China Pacific Insurance's subsidiary, China Pacific Life, reported a cumulative premium income of 241.32 billion yuan for the first ten months, a year-on-year increase of 9.9% [1] - China Pacific Property Insurance, another subsidiary, achieved a cumulative premium income of 173.57 billion yuan, with a year-on-year growth of 0.4% [1] - Nocera Biopharma reported a net loss of 64.41 million yuan for the first three quarters, despite a revenue increase of 59.85% to 1.115 billion yuan [1] Group 2 - Founder Securities received approval from the China Securities Regulatory Commission to issue short-term corporate bonds not exceeding 5 billion yuan [1] - Haicheng Bonda's director plans to reduce his stake by up to 0.97%, equating to 198,400 shares [1] - Yuyuan Group intends to repurchase shares worth between 200 million and 300 million yuan, with a maximum price of 8.60 yuan per share [1] Group 3 - Huaren Shuanghe's subsidiary passed the GMP compliance inspection for a specific diabetes medication [4] - Lichong Group received project notifications from three international automotive manufacturers, with expected sales amounting to approximately 1.135 billion yuan [6] - Deyang Co. is planning to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy [7] Group 4 - Longxin General announced the transfer of its entire stake in a subsidiary for 105.6 million yuan, and also plans to divest another stake for 1 yuan due to poor performance [16] - Kangda New Materials decided to terminate the acquisition of a semiconductor company due to unsatisfactory due diligence progress [17] - Lu'an Environmental reported a 3.28% year-on-year increase in coal sales for October, totaling 3.78 million tons [18] Group 5 - Shanghai Port Group plans to invest 2 billion yuan to establish a new holding company with several state-owned enterprises [20] - Borui Pharmaceutical's new drug for obesity treatment has received clinical trial approval [23] - Silver Dragon Co. has completed the registration of a new energy industry fund focusing on high-growth potential projects [24] Group 6 - Hengrui Medicine received approval for a clinical trial of a prostate cancer drug [11] - Baiji Shenzhou reported a net profit of 1.139 billion yuan for the first three quarters, marking a turnaround from losses [36] - Huasheng Pharmaceutical's special medical food product has received registration certification [60]

Group 1 - Longjian Co., Ltd. won a bid for a highway maintenance project in Heilongjiang with a contract value of 483 million yuan, accounting for 2.64% of the company's expected revenue for 2024 [1] - Transsion Holdings plans to issue H-shares and list on the main board of the Hong Kong Stock Exchange [1] - Good Home's controlling shareholder intends to reduce its stake by up to 2.7%, equivalent to no more than 39.4468 million shares [1][2] Group 2 - Xinhua Insurance reported a cumulative premium income of 181.973 billion yuan from January to October, representing a year-on-year growth of 17% [2][4] - Zhejiang Jiaokao is part of a consortium that plans to bid for a new urbanization project with an estimated total investment of 11.103 billion yuan [4] Group 3 - Changchun High-tech received approval for clinical trials of a vaccine for adolescents and adults [6] - XinNuoWei's application for the listing of Pertuzumab injection has been accepted, targeting HER2-positive breast cancer [8] - Dash Smart won a bid for an intelligent project at the new Huanggang Port inspection building, valued at 55.056 million yuan, which is 1.74% of its expected revenue for 2024 [8] Group 4 - Electronic City is involved in a lawsuit for debt recovery, with the amount in dispute estimated at 777 million yuan [9] - Haibo Technology signed a strategic cooperation agreement with CATL for a cumulative procurement of no less than 200 GWh of electricity from 2026 to 2028 [10] Group 5 - Renfu Pharmaceutical's HW231019 tablets have entered the second phase of clinical trials for postoperative pain relief [11] - Tonghua Dongbao received a drug registration certificate for Aspart Insulin injection from the Dominican Republic [11] Group 6 - Shaanxi Construction reported winning major projects worth a total of 1.016 billion yuan in October [12] - Fuzhou Environmental Protection plans to change its stock name to "Fuzhou Technology" [12] Group 7 - Panlong Pharmaceutical's gel patch for knee osteoarthritis has received approval for clinical trials [15] - Zhongyida's application for a specific stock issuance has been terminated by the Shanghai Stock Exchange [16] Group 8 - Zhizhong Home's controlling shareholder reduced its holdings of convertible bonds by 905,000 units, accounting for 13.51% of the total issued [19] - Haibo Co., Ltd. plans to establish a subsidiary with an investment of 1 billion yuan for high-end component projects [21] Group 9 - Caina Co. plans to use 57 million yuan of idle funds to purchase structured deposits [23] - Zhendong Pharmaceutical's new drug for acute ischemic stroke has entered the IIa phase of clinical trials [25] Group 10 - Weiman Sealing's overseas subsidiary plans to lease a factory in Saudi Arabia for 5 years at a total rent of approximately 54.039 million yuan [26] - Yiling Pharmaceutical's application for Memantine Hydrochloride has been approved for market entry [28] Group 11 - Dongfang Zhizao plans to acquire 70% of Saifu Machinery for 27.4887 million yuan [30] - JianKai Technology's actual controller intends to transfer 3% of the company's shares through inquiry [31] Group 12 - Rejing Bio plans to repurchase shares worth between 100 million and 200 million yuan [32] - Bangji Technology has decided to terminate a major asset restructuring project due to failure to reach an agreement [34] Group 13 - Huadong Pharmaceutical's application for the marketing license of a new drug has been accepted [36] - Zhonggu Logistics' shareholder plans to reduce its stake by up to 3% [38] Group 14 - Bohui Innovation's subsidiary received approval for a clinical trial of a vaccine for invasive infections [40] - Shannon Chip's shareholder pledged 0.27% of the company's shares for financing [42] Group 15 - Shanghai Petrochemical appointed a new general manager [44] - Jiaojian Co. plans to reduce the holdings of some directors and executives by up to 0.35% [46] Group 16 - Weiting Electric plans to raise no more than 300 million yuan through a private placement [47] - Zhongjin Irradiation plans to invest approximately 200 million yuan in an electronic accelerator manufacturing project [49] Group 17 - Tongxing Technology signed a framework agreement to invest 3.2 billion yuan in a sodium battery project [50] - Hongri Da plans to establish a subsidiary focused on semiconductor packaging [51] Group 18 - Shanghai Kaibao's new drug for acute ischemic stroke has received approval for clinical trials [53] - Yitong Century announced a change in its control structure, becoming a company without a controlling shareholder [55]

Group 1 - China Power Construction Corporation's stock price decreased by 2.05% to 5.73 CNY per share, with a total market capitalization of 98.706 billion CNY as of November 12 [1] - The company experienced a net outflow of 142 million CNY in principal funds, with significant selling pressure observed [1] - Year-to-date, the stock has increased by 7.44%, but has seen a decline of 2.22% over the past 20 days and 8.76% over the past 60 days [1] Group 2 - China Power Construction Corporation, established on November 30, 2009, primarily engages in construction contracting, power investment and operation, real estate development, and equipment manufacturing [2] - The company's revenue composition shows that engineering contracting and surveying design account for 90.84% of total revenue, while power investment and operation contribute 4.23% [2] - As of September 30, 2025, the company reported a revenue of 439.553 billion CNY, reflecting a year-on-year growth of 3.10%, while net profit attributable to shareholders decreased by 15.13% to 7.474 billion CNY [2] Group 3 - Since its A-share listing, China Power Construction has distributed a total of 19.31 billion CNY in dividends, with 6.606 billion CNY distributed over the past three years [3] - As of September 30, 2025, the top ten circulating shareholders include China Securities Finance Corporation and Hong Kong Central Clearing Limited, with notable changes in shareholding [3]

Core Viewpoint - Sichuan Road and Bridge experienced a stock price decline of 2.03% on November 12, with a current price of 9.63 CNY per share and a total market capitalization of 83.739 billion CNY [1] Financial Performance - For the period from January to September 2025, Sichuan Road and Bridge achieved a revenue of 73.281 billion CNY, representing a year-on-year growth of 1.95%, and a net profit attributable to shareholders of 5.300 billion CNY, which is an increase of 11.04% year-on-year [2] Shareholder Information - As of September 30, 2025, the number of shareholders for Sichuan Road and Bridge reached 60,500, an increase of 20.10% compared to the previous period, while the average circulating shares per person decreased by 16.59% to 110,993 shares [2] Dividend Distribution - Since its A-share listing, Sichuan Road and Bridge has distributed a total of 18.855 billion CNY in dividends, with 14.054 billion CNY distributed over the past three years [3] Major Shareholders - As of September 30, 2025, the top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 96.117 million shares, a decrease of 18.469 million shares from the previous period [3]

Core Viewpoint - The stock of Jiangjian Co., Ltd. has shown significant growth this year, with a year-to-date increase of 156.56%, indicating strong market performance and investor interest [1][2]. Financial Performance - For the period from January to September 2025, Jiangjian Co., Ltd. achieved a revenue of 3.021 billion yuan, representing a year-on-year growth of 6.06% [2]. - The net profit attributable to shareholders for the same period was 137 million yuan, reflecting a substantial year-on-year increase of 36.40% [2]. - The company has distributed a total of 296 million yuan in dividends since its A-share listing, with 154 million yuan distributed over the past three years [3]. Stock Market Activity - As of November 7, the stock price of Jiangjian Co., Ltd. was 14.28 yuan per share, with a trading volume of 126 million yuan and a turnover rate of 1.45%, resulting in a total market capitalization of 8.838 billion yuan [1]. - The stock has seen a net outflow of 9.2156 million yuan in principal funds, with significant buying and selling activity from large orders [1]. - The company has appeared on the stock market's "Dragon and Tiger List" once this year, with the last occurrence on January 7 [1]. Business Overview - Jiangjian Co., Ltd. is primarily engaged in the construction of highways and municipal infrastructure, with 71.73% of its revenue derived from these activities [1]. - The company also engages in housing construction and sales of building materials, contributing 14.18% and 10.03% to its revenue, respectively [1]. - The company is classified under the construction and decoration industry, specifically in the municipal engineering sector, and is associated with concepts such as the Belt and Road Initiative and rural revitalization [2].

Core Viewpoint - Sichuan Road and Bridge experienced a stock price increase of 44.08% year-to-date, with significant gains in recent trading days, indicating strong market performance and investor interest [1][2]. Financial Performance - For the period from January to September 2025, Sichuan Road and Bridge reported a revenue of 732.81 billion yuan, reflecting a year-on-year growth of 1.95%. The net profit attributable to shareholders was 53.00 billion yuan, marking an 11.04% increase compared to the previous year [2]. - The company has distributed a total of 188.55 billion yuan in dividends since its A-share listing, with 140.54 billion yuan distributed over the last three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for Sichuan Road and Bridge increased to 60,500, a rise of 20.10% from the previous period. The average number of circulating shares per shareholder decreased by 16.59% to 110,993 shares [2]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 96.12 million shares, a decrease of 18.47 million shares from the previous period [3]. Market Activity - On November 5, the stock price of Sichuan Road and Bridge rose by 2.06%, reaching 9.90 yuan per share, with a trading volume of 2.31 billion yuan and a turnover rate of 0.35%. The total market capitalization stood at 860.86 billion yuan [1]. - The net inflow of main funds was 1.7275 million yuan, with significant buying and selling activity from large orders [1].